Almac supports COVID-19 studies in Africa

By Jenni Spinner contact

- Last updated on GMT

(Khosrork/iStock via Getty Images Plus)
(Khosrork/iStock via Getty Images Plus)

Related tags: Almac, Clinical trial, COVID-19, Coronavirus

The CDMO has landed a grant from the Bill and Melinda Gates Foundation’s COVID-19 Therapeutics Accelerator for clinical research in the sub-Saharan region.

Almac Group, a contract development and manufacturing organization (CDMO) based in Northern Ireland, has received a $288,000 grant to support clinical research pursuing COVID-19 solutions in sub-Saharan Africa. The funding comes from the COVID-19 Therapeutics Accelerator, an initiative by the Bill and Melinda Gates Foundation, Wellcome and MasterCard.

An Almac spokesperson told Outsourcing-Pharma that the company had collaborated with the Gates Foundations on previous projects. For this COVID-19 project, the company was brought in by R&D supply chain specialists Brizzey.

According to the spokesperson, the research team will work to discover effective treatments for the virus behind the global pandemic.

Currently there are no broad-spectrum antivirals or immunotherapies available for the fight against emerging pathogens and no proven treatments approved for use against COVID-19​,” they told us. “The COVID-19 Therapeutics Accelerator is a philanthropic initiative designed to coordinate R&D efforts, remove barriers to drug development and scale up treatments to address the pandemic.​”

The COVID-19 Therapeutics Accelerator receives funding from an array of public and philanthropic donors. Its mission is to speed the response to the COVID-19 pandemic by supporting efforts to identify, assess, develop and scale up treatments for the virus.

Almac Clinical Services will contribute various clinical trial solutions to the project, from protocol through to patient delivery. Its Almac Sciences arm will offer analytical support, direct from its global headquarters in Craigavon, Northern Ireland.

Additionally, in an effort to accelerate drug development, Almac Clinical Services has received the active drug and is providing over encapsulation services, manufacturing a placebo match, packaging and labelling the supplies to support this blinded clinical trial. Almac Sciences will conduct analytical and stability testing for the investigational drug.

Robert Dunlop, managing director and president for Almac Clinical Services, said the research will take place in an area of the world harder hit than most by the virus.

Almac’s global capabilities and expertise enables us to play our part and support efforts to find a vaccine and/or treatment for coronavirus​,” Dunlop said. “We are delighted to be awarded this grant from the COVID-19 Therapeutics Accelerator and to be supporting these clinical studies in sub-Saharan Africa​.”

Almac Clinical Services will ship trial supplies to the site, logistics and distribution of the drug for safe delivery to patients during the investigation. The COVID-19 study is being headed up by an African principal investigator.

Additionally, Almac is supporting a second open-label clinical study through the distribution of commercial packs to a pharmacy in South Africa.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars